2017 U.K. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Country Segment Forecasts, Emerging Technologies, Competitive Strategies [Updated: 30032017] Prices from USD $1850

07:48 EDT 6 Jun 2017 | BioPortfolio Reports

Complete report $1,850. nbsp;DataPack test volumes, sales forecasts, supplier shares $1,200.

The report is available by section, market segment, and can be customtailored to your specific information needs and budget.

This new study from VPGMarketResearchnbsp;contains 408 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Report Highlights

Market shares of leading suppliers
Business and technological trends in major markets
Fiveyear test volume and sales forecasts
Market shares of leading competitors
Feature comparison of major analyzers
Strategic profiles of leading market players and startup firms developing innovative products
Specific product and business opportunities for instrument and consumable suppliers.


Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of costeffective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

U.K. Market Overview

Laboratories performing DNA sequencing and molecular diagnostic testingnbsp;by country and market segment.

Fiveyear test volume and sales projections.

Market Segmentation Analysis

Fiveyear test volume and sales projections:

Infectious Diseasesnbsp;nbsp;nbsp;nbsp;nbsp; nbsp;nbsp; Forensic Testing
Cancernbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; Paternity Testing/HLA Typing
Genetic Diseasesnbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; nbsp;nbsp;nbsp;nbsp; Others

  • A comprehensive analysis of the sequencing market by laboratory segment.

    Detailed market segmentation analysis, including review of the market dynamics, trends,
    nbsp; structure, size, growth and major suppliers.

    Product/Technology Review

    Comparison of the major molecular diagnosticnbsp;analyzers.

    Extensive review of molecular diagnostic technologies, test formats, detection methodologies,
    nbsp; trends in testing automation and over target/signal amplification methods.

    Worldwide listings of companies, universities and research centers developing new molecular
    nbsp;nbsp; diagnosticnbsp;technologies and products.

    Competitive Assessments

    Extensive strategic assessments of major suppliers and emerging market entrants,
    nbsp;nbsp;including their sales, product portfolios, marketing tactics, collaborative arrangements and
    nbsp;nbsp;new technologies/products in Ramp;D.

    nbsp;nbsp; Abbott
    nbsp;nbsp; Affymetrix
    nbsp;nbsp; Agilent Technologies
    nbsp;nbsp; Applied Gene Technologies
    nbsp;nbsp; Arca Biopharma
    nbsp;nbsp; Beckman Coulter/Danaher
    nbsp;nbsp; Becton Dickinson
    nbsp;nbsp; Biokit
    nbsp;nbsp; BioMerieux
    nbsp;nbsp; BioRad
    nbsp;nbsp; Biotest
    nbsp;nbsp; CellMark Forensics/LabCorp
    nbsp;nbsp; Cepheid
    nbsp;nbsp; Decode Genetics
    nbsp;nbsp; Diadexus
    nbsp;nbsp; Eiken
    nbsp;nbsp; Elitech Group
    nbsp;nbsp; Enzo
    nbsp;nbsp; Exact Sciences
    nbsp;nbsp; Fujirebio
    nbsp;nbsp; Grifols
    nbsp;nbsp; Hologic/GenProbe
    nbsp;nbsp; Illumina
    nbsp;nbsp; Kreatech/Leica
    nbsp;nbsp; LiCor Biosciences
    nbsp;nbsp; Monogram Biosciences
    nbsp;nbsp; Myriad Genetics
    nbsp;nbsp; OrthoClinical Diagnostics
    nbsp;nbsp; Perkin Elmer/Caliper
    nbsp;nbsp; Proteome Sciences
    nbsp;nbsp; Qiagen
    nbsp;nbsp; Roche
    nbsp;nbsp; Scienion
    nbsp; nbsp; Sequenom
    nbsp; nbsp; Shimadzu
    nbsp; nbsp; Siemens
    nbsp; nbsp; Sierra Molecular
    nbsp; nbsp; Takara Bio
    nbsp; nbsp; Tecan Group
    nbsp;nbsp; Thermo Fisher

    Comprehensive listings of companies developing and marketing molecular
    nbsp; diagnostic products, by test and application.

    Opportunities and Strategic Recommendations

    Specific new product development opportunities with potentially significant market appeal
    nbsp;nbsp;during the next five years.

    Design criteria for new products.

    Alternative market penetration strategies.

    Potential market entry barriers and risks.

    Business planning issues and concerns.

    Contains 408 pages

    Original Article: 2017 U.K. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Country Segment Forecasts, Emerging Technologies, Competitive Strategies [Updated: 30032017] Prices from USD $1850


    More From BioPortfolio on "2017 U.K. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Country Segment Forecasts, Emerging Technologies, Competitive Strategies [Updated: 30032017] Prices from USD $1850"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...